Pulmonary Arterial Hypertension (PAH): How to Develop an Effective Risk Reduction Strategy

preview_player
Показать описание
Learn how to develop an effective clinical-risk reduction strategy to optimize treatment of patients with pulmonary arterial hypertension (PAH).

More content about PAH is available for AMA PRA Category 1 Credit(s)™

This video is supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson. Developed for physicians and advance practice providers.
Рекомендации по теме